Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
Date:4/29/2008

ion from 2:00 p.m. to 6:00 p.m. local time on

Sunday, June 1, 2008.

-- "Dose effect of ipilimumab in patients with advanced melanoma: results

from a phase 2, randomized, dose-ranging study" (Abstract #9025,

Melanoma Session) -- Poster presentation and discussion from 2:00 p.m.

to 6:00 p.m. local time on Sunday, June 1, 2008.

-- "Prolonged survival in objective responders to ipilimumab therapy"

(Abstract #20004) -- Publication only.

Response and Safety Data of Ipilimumab in Prostate

-- "Phase 1 trial of ipilimumab (IPI) alone and in combination with

radiotherapy (XRT) in patients with metastatic castration resistant

prostate cancer (mCRPC)" (Abstract #5004, New Targeted Strategies for

Patients with Prostate Cancer Session) -- Oral presentation beginning

at 11:30 a.m. local time on Monday, June 2, 2008.

-- "Expanded phase 1 combination trial of GVAX immunotherapy for prostate

cancer and ipilimumab in patients with metastatic hormone-refractory

prostate cancer (mHRPC)" (Abstract #5146, Genitourinary Cancer Session)

-- Poster presentation from 8:00 a.m. to 12:00 p.m. local time on

Saturday, May 31, 2008.

Clinical and Preclinical Data of Additional Immunotherapy and Antibody-Drug Conjugate Programs

-- "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal

antibody, in patients with selected refractory or relapse malignancies"

(Abstract #3006, Developmental Therapeutics: Immunotherapy

Session) -- Oral presentation beginning at 4:00 p.m. local time on

Saturday, May 31, 2008.

-- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in

combination with ixabepilone in preclinical tumor models" (Abstract

#3048, Developmental Therapeutics: Immunotherapy Session) -- Poster

presentation from 2:00 p.m. to 6:00 p.m. loca
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Medarex Announces Ipilimumab Program Continues to Move Forward
3. Medarex to Receive Milestone Payment from Amgen
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
7. XTENT Announces First Quarter 2008 Financial Results
8. Neuralstem Announces Issuance of Core Technology Patent in Europe
9. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
10. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Shakti, LLC, today announced that it has changed its name ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... our transformation into a company focused on patent claim analysis ... validity." In ... the Company commenced a corporate re-branding initiative in order to ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... pharmacy was launched after the company had studied the market ... reliable and trustworthy places to shop for high quality prescription ... launching a website that would offer a full range of ... patience. The new drugstore is bound to become a popular ...
... 16 Novartis announced today that new six-year data ... Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) ... this weekend at the annual meeting of the American ... ON, Canada. The study showed that Reclast ...
Cached Medicine Technology:New Online Pharmacy RxBuys.com is Launched by One of the Leading Pharmaceutical Companies, Rx Corp 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... to announce its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and ... It features revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Eligibles Database have added comprehensive information on two new duals programs: Rhode ... December 2015 launch; and Idaho’s partnership to revamp Blue Cross of Idaho’s ...
(Date:8/28/2015)... MO (PRWEB) , ... August 28, 2015 , ... ... testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement Therapy Products ... a cap on the number of custodial files the PSC may receive for ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Super-Sod launched ... new look and updated navigation. The most notable change is the responsive web design. ... other smart devices. Customers can easily submit quote requests for sod, sign-up for the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Wilson and Juanita ... disease prevention, improving a patient’s quality of life through early diagnosis and treatment. ... disease, cancer, diabetes, HIV/AIDS, STDs, and others. A Women’s, Infants & Children (WIC) ...
Breaking Medicine News(10 mins):Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:Health Clinic Opening and Public Art Unveiling 2
... National Football League (NFL) will give a $1 million ... Traumatic Encephalopathy (CSTE) at Boston University School of Medicine ... funds will be used to continue the Center,s ground-breaking ... in athletes, in particular football players. CSTE researchers have ...
... Minn. -- The growing number of Americans with cardiovascular ... of chest pain. In a study published in the ... reported that patients dismissed from the hospital with noncardiac ... highlight a need for more aggressive cardiovascular risk factor ...
... for inflammation , TUESDAY, April 20 (HealthDay News) -- ... have something to do with components of virgin olive ... study reports. , "These findings strengthen the relationship between ... most basic level of healthy effects derived from virgin ...
... ... , ... 20, 2010 -- As the debate around legalization intensifies from coast to coast, CNBC.com ... of business. "Marijuana & Money" thoroughly examines the current marketplace as well as ...
... ... $2500 so far in a weight loss challenge, benefiting City CURE’s Whiz Kids program. Dr. ... is to raise $3000. City CURE is a non-profit organization in Cincinnati whose goal is ... ...
... "I was ... her pancreatic cancer. But the Chicago woman refused to give up in her fight ... Hepatobiliary Diseases at Northwest Community Hospital in Arlington Heights, where the expertise of Dr. Malcolm ... ...
Cached Medicine News:Health News:NFL gives $1 million unrestricted gift to Boston University to study impact of brain injuries 2Health News:NFL gives $1 million unrestricted gift to Boston University to study impact of brain injuries 3Health News:Outcomes of patients dismissed from the hospital with non-cardiac chest pain 2Health News:CNBC.com Presents "Marijuana & Money" 2Health News:CNBC.com Presents "Marijuana & Money" 3Health News:CNBC.com Presents "Marijuana & Money" 4Health News:Dr. Sachin Patel Partners with City CURE to Raise $3000 in a Pound-4-Pound Challenge Benefiting Whiz Kids 2Health News:Given No Chance to Survive with Pancreatic Cancer, Chicago Woman Finds New Life at Northwest Community Hospital 2Health News:Given No Chance to Survive with Pancreatic Cancer, Chicago Woman Finds New Life at Northwest Community Hospital 3
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
Medicine Products: